OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Hematology & Oncology is 57. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	722
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	688
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases	686
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	661
Recent advances in targeting protein degradation for tumor immunotherapy	651
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	577
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	443
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	421
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	410
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	380
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	366
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	354
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	343
Cancer vaccines: current status and future directions	330
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	300
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	297
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis	293
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	266
Landscape of biallelic DNMT3A mutant myeloid neoplasms	263
Personalized nanovaccines for treating solid cancer metastases	241
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	226
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation	221
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	218
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors	218
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	213

Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression	208
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	206
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	201
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	198
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	189
Ferroptosis: principles and significance in health and disease	189
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	189
Recent advances in therapeutic strategies for non-small cell lung cancer	184
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	182
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	179
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?	177
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer	172
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology	168
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation	165
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	163
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	160
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	152
Small RNA modifications: regulatory molecules and potential applications	149
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	149
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia	146
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients	146
3D chromatin architecture and transcription regulation in cancer	141
Recent advances in targeted strategies for triple-negative breast cancer	141
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	138
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	138
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	138
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials	137
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	137
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	136
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	135
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	131
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	130
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure	129
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	129
A single-cell and spatially resolved atlas of human osteosarcomas	129
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth	128
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies	128
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma	122
Target neutrophil heterogeneity and plasticity in cancer	121
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	120
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting	119
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	116
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	115
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	115
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype	115
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	114
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects	114
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	112
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	112
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	112

Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer	111
The functional and clinical roles of liquid biopsy in patient-derived models	106
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	105
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies	104
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	104
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	103
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	97
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	96
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	94
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	94
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	93
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	93
Worked to the bone: antibody-based conditioning as the future of transplant biology	91
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies	91
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	91
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	91
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination	90
A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	90
Challenges and new technologies in adoptive cell therapy	88
Gastric cancer treatment: recent progress and future perspectives	85
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	84
The long and short non-coding RNAs modulating EZH2 signaling in cancer	83
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	83
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders	82
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	82
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	82
Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy	82
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	80
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	80
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	79
Targeting GPRC5D for multiple myeloma therapy	79
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies	78
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma	75
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	74
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation	74
Metabolic reprogramming in the tumor microenvironment of liver cancer	74
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	73
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses	73
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	72
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	72
Correction: Immunosenescence: a key player in cancer development	71
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	70
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	69
PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy	68
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	68
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	68
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	67
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	66
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	66
Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial	65
Momelotinib: an emerging treatment for myelofibrosis patients with anemia	65
Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee	63
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy	63
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	62
Advances in targeting histone deacetylase for treatment of solid tumors	61
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	61
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	60
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	60
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	59
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	59
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status	59
Racial disparities in clonal hematopoiesis and their impact on hematologic malignancies	58
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities	57
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho	57
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry	57